Successful treatment with autologous peripheral blood stem cell transplantation for acquired immunodeficiency syndrome (AIDS)-related malignant lymphoma. 2009

Yuya NAGAI, and Minako MORI, and Daichi INOUE, and Takaharu KIMURA, and Sonoko SHIMOJI, and Katsuhiro TOGAMI, and Sumie TABATA, and Akiko MATSUSHITA, and Kenichi NAGAI, and Yukihiro Imai, and Toshiro Takafuta, and Takayuki Takahashi
Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital.

A 62-year-old man was diagnosed with human immunodeficiency virus (HIV) infection while suffering from recurrent herpes zoster infection. Laboratory examination revealed CD4(+) lymphocyte count 16 cells/mul and HIV loading 150,000 copies/ml at presentation. In addition, he had multiple lymph node swelling. Histologic diagnosis of a biopsied lymph node was diffuse, large, B cell-type malignant lymphoma. The karyotype of the lymphoma cells was t(8;14)(q24;q32), which was confirmed by G-banding and fluorescent in situ hybridization. Positron emission tomography (PET)-combined CT scanning revealed systemic extranodal tumors involving the gastrointestinal tract, pancreas, and bone marrow. The clinical stage of the lymphoma was IVB and the international prognosis index was categorized as high. Complete remission (CR) of the lymphoma was obtained after 2 courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) chemotherapy and 4 subsequent courses of rituximab-combined CHOP (R-CHOP). Highly active antiretroviral therapy (HAART) was started at the initiation of CHOP. Because of the poor prognosis of AIDS-related lymphoma, he received autologous peripheral blood stem cell transplantation with the MEAM protocol (ranimustine, etoposide, cytarabine, melphalan) as a conditioning procedure without a severe infectious episode. He remains in CR 24 months after the transplantation.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069283 Rituximab A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. CD20 Antibody, Rituximab,GP2013,IDEC-C2B8,IDEC-C2B8 Antibody,Mabthera,Rituxan,IDEC C2B8,IDEC C2B8 Antibody,Rituximab CD20 Antibody
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

Yuya NAGAI, and Minako MORI, and Daichi INOUE, and Takaharu KIMURA, and Sonoko SHIMOJI, and Katsuhiro TOGAMI, and Sumie TABATA, and Akiko MATSUSHITA, and Kenichi NAGAI, and Yukihiro Imai, and Toshiro Takafuta, and Takayuki Takahashi
December 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
Yuya NAGAI, and Minako MORI, and Daichi INOUE, and Takaharu KIMURA, and Sonoko SHIMOJI, and Katsuhiro TOGAMI, and Sumie TABATA, and Akiko MATSUSHITA, and Kenichi NAGAI, and Yukihiro Imai, and Toshiro Takafuta, and Takayuki Takahashi
December 2000, Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University,
Yuya NAGAI, and Minako MORI, and Daichi INOUE, and Takaharu KIMURA, and Sonoko SHIMOJI, and Katsuhiro TOGAMI, and Sumie TABATA, and Akiko MATSUSHITA, and Kenichi NAGAI, and Yukihiro Imai, and Toshiro Takafuta, and Takayuki Takahashi
June 2008, Clinical lymphoma & myeloma,
Yuya NAGAI, and Minako MORI, and Daichi INOUE, and Takaharu KIMURA, and Sonoko SHIMOJI, and Katsuhiro TOGAMI, and Sumie TABATA, and Akiko MATSUSHITA, and Kenichi NAGAI, and Yukihiro Imai, and Toshiro Takafuta, and Takayuki Takahashi
October 2005, Archives of dermatology,
Yuya NAGAI, and Minako MORI, and Daichi INOUE, and Takaharu KIMURA, and Sonoko SHIMOJI, and Katsuhiro TOGAMI, and Sumie TABATA, and Akiko MATSUSHITA, and Kenichi NAGAI, and Yukihiro Imai, and Toshiro Takafuta, and Takayuki Takahashi
February 1998, Bone marrow transplantation,
Yuya NAGAI, and Minako MORI, and Daichi INOUE, and Takaharu KIMURA, and Sonoko SHIMOJI, and Katsuhiro TOGAMI, and Sumie TABATA, and Akiko MATSUSHITA, and Kenichi NAGAI, and Yukihiro Imai, and Toshiro Takafuta, and Takayuki Takahashi
November 2003, Internal medicine (Tokyo, Japan),
Yuya NAGAI, and Minako MORI, and Daichi INOUE, and Takaharu KIMURA, and Sonoko SHIMOJI, and Katsuhiro TOGAMI, and Sumie TABATA, and Akiko MATSUSHITA, and Kenichi NAGAI, and Yukihiro Imai, and Toshiro Takafuta, and Takayuki Takahashi
May 1997, Bone marrow transplantation,
Yuya NAGAI, and Minako MORI, and Daichi INOUE, and Takaharu KIMURA, and Sonoko SHIMOJI, and Katsuhiro TOGAMI, and Sumie TABATA, and Akiko MATSUSHITA, and Kenichi NAGAI, and Yukihiro Imai, and Toshiro Takafuta, and Takayuki Takahashi
November 2000, Muscle & nerve,
Yuya NAGAI, and Minako MORI, and Daichi INOUE, and Takaharu KIMURA, and Sonoko SHIMOJI, and Katsuhiro TOGAMI, and Sumie TABATA, and Akiko MATSUSHITA, and Kenichi NAGAI, and Yukihiro Imai, and Toshiro Takafuta, and Takayuki Takahashi
December 2007, Neuromuscular disorders : NMD,
Yuya NAGAI, and Minako MORI, and Daichi INOUE, and Takaharu KIMURA, and Sonoko SHIMOJI, and Katsuhiro TOGAMI, and Sumie TABATA, and Akiko MATSUSHITA, and Kenichi NAGAI, and Yukihiro Imai, and Toshiro Takafuta, and Takayuki Takahashi
June 1998, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Copied contents to your clipboard!